1. Market Research
  2. > Pharmaceutical Market Trends
Multiple Sclerosis: Payer Insight

Multiple Sclerosis: Payer Insight

  • July 2016
  • ID: 4201012
  • Format: PDF
  • Firstword Pharma

Summary

Table of Contents




Drug prices rising while needs remain unmet. Now payers are fighting back
Payers have had it with the high cost of Multiple Sclerosis (MS) drugs and now they’re fighting back—demanding better data to justify pricing, and using a host of strategies to offset and contain costs. Get the details in Payer Insight: Multiple Sclerosis. You’ll learn what drives treatment costs up, what payers are doing to bring them down, why assessing cost effectiveness for MS drugs is so difficult, and how payers make access and reimbursement decisions.
We interviewed 12 US and EU payers with expertise in formulary development and drug reimbursement to get their perspective on the challenges facing the MS market. Plus you’ll find out how payers view pipeline MS treatments, what advice they have for Pharma, and which clinical trials to watch.
“…it is not the insurance companies that are causing those co-pays to increase. It is the doing of the pharmaceutical industry.”
- Pharmacy Director, Pharmacy Benefit Manager Order the report and you’ll receive three quarterly FirstWord Therapy Trends Update Bulletins free!








Top takeaways

Ripple effect: Rising drug costs put pressure on other needed treatments for MS patients. Do payers envision a time when patients may have to go without?
Cost-effectiveness difficult to assess: What information are payers missing in order to measure cost-effectiveness? How will it influence PR and MA decisions?
Route of administration: The way drugs are administered has important consequences that affect cost and adherence, and shape payers’ decisions.
What about biosimilars and generics? Will they displace branded MS treatments, or are payers simply using them as a negotiating tool? Learn what will determine their near-term prospects.
Needs remain unmet: Current disease modifying agents only do so much. Payers point to four main areas of unmet clinical need that affect the MS pricing landscape in different ways.

A payers’ eye view

Cost containment: Payers are experimenting with a number of discounting, contracting, and payment schemes to contain drug costs. Which ones are showing the most promise?
Complex PR and MA decisions: Payers predict several factors will affect pricing, reimbursement, and market access decisions in the near term. Which ones will have the greatest impact?
Poor adherence: Patient adherence is key to assessing efficacy, but difficult to achieve. How does adherence affect drug choice, and what are payers doing to understand and improve it?
Lack of data: With little efficacy data to support MS drugs’ high prices, payers are pushing back. What data are they demanding? How will it affect future drug launches and access decisions?
Drugs Summary: Get a breakdown of approved and pipeline drugs, as well as payers’ thoughts about several oral, subcutaneous, and infusion therapies.
Coverage and access recap: Learn how coverage and access decisions are made in the US and several EU countries, and what payers are doing to improve transparency. Includes an update on Obamacare for US readers.
Clinical trials to watch: A comprehensive list of important upcoming trials for approved and pipeline products gives you a window into how the treatment landscape may evolve.
Warnings for pharma: Payers identify the two key things providers have to do if they want to avoid past mistakes.


Payers interviewed
We interviewed 6 US payers and 6 from the EU. All interviewees have expertise in formulary development and drug reimbursement. All respondents requested that their details remain confidential.

US Payers
Pharmacy Director, Pharmacy Benefit Manager
Chief Medical Officer, Managed Care Organisation
Chief Medical Officer, PMT Chair, Managed Care Organisation
Pharmacy Director, Community Health Plan
Medical Director, Managed Care Organisation
Pharmacy Director, Health Maintenance Organisation

EU Payers
Regional Pharmaceutical and Formulary Advisor, UK
Chief Hospital Pharmacist, Vice President Formulary Drug Committee, France
Pharmacist Director, France
Head of Drug Reimbursement, Germany
Member of the Drug Commission, Germany Medical Association, Germany
Chief Pharmacist, UK

Money Back Guarantee
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.



Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Global VOC Gas Monitor Market 2021-2025

  • $ 2500
  • January 2021
  • 120 pages

Global VOC gas monitor market 2021-2025 The analyst has been monitoring the VOC gas monitor market and it is poised to grow by $ 50.05 mn during 2021-2025, progressing at a CAGR of 5% during the forecast ...

  • World
  • Financial Consulting
  • Wastewater Treatment
  • Industry analysis

ref:plp2016

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on